JOHNSON & JOHNSON

Johnson & Johnson files Form 144: 15,000 shares sold by officer Jennifer Taubert – a routine insider sale that meets Rule 144, little market impact, but key for investors tracking corporate governance.

Johnson & Johnson’s stock dipped amid a market pullback, but its robust pipeline—from CAR‑T to gene therapy and mRNA vaccines—signals long‑term growth and investor resilience.

Johnson & Johnson’s latest executive share sale reveals how liquidity management fuels biopharma strategy—market access, patent cliffs, and M&A insights.

Johnson & Johnson’s latest stock stability reflects robust oncology pipelines, strategic partnerships, and strong cash flow that keep it poised for growth amid patent cliffs.

J&J’s new Ottava robot, cleared by the FDA, could reshape minimally invasive surgery with AI‑driven precision, lower costs, and high‑value reimbursement, promising robust investor upside.

Explore how Johnson & Johnson’s ovarian‑cancer settlement and Rybrevant’s FDA priority review impact its stock, while new IBD therapy shows promise for future growth.

Johnson & Johnson’s $1.2 billion Firefly Bio deal and Sail Biomedicines partnership boost oncology and CAR‑T portfolios, offering patent protection and high‑growth market access.

Johnson & Johnson’s $5.5 B talc settlement: how the payout, investor confidence, and product‑liability risks reshape its finances and brand.

J&J’s $5.5 billion talc settlement shifts focus to high‑margin oncology, immunology and rare‑disease R&D while cutting legal risk and aligning with value‑based reimbursement.

J&J’s modest stock rise shows investor confidence in its strategic push into the booming psychedelic‑adjacent neuroscience market, backed by smart pricing, payer engagement, and targeted M&A to drive $3‑$5 bn in first‑five‑year revenue.